THU0445

PRIMARY DIAGNOSIS OF LARGE VESSEL VASCULITIS BY TISSUE HISTOLOGY AFTER SURGERY OF AORTIC VALVE AND ASCENDING AORTA

G. Assmann¹, I. Karlova², F. Langer², M. Schreiber³, M. Pfeundschnuh¹, H.-J. Schaefers². ¹Rheumatology and Oncology, ²Thoracic Surgery, ³Radiology Imaging, University Medical School of Saarland, Homburg, Germany

Background: Large vessel vasculitis showed different histological patterns, ranging from well-formed granulomas and lymphoplasmacytic pattern to giant cell pattern. Most of entities of large vessel vasculitis belong to rheumatic diseases such as the giant cell arteritis (GCA). The clinical feature is very variable depending on the GCA manifestations.

Objectives: Here we present an observation study of non-vasculitis patients, which had to undergo surgery of aortic valve and/or ascending aorta with a tissue histology of aortic inflammation.

Methods: In the department of thoracic surgery of the University Medical School of Saarland, Germany, 1474 patients (in 2014 n=806, in 2015 n=668) underwent thoracic surgery of aortic valve or ascending aorta due to different indications such as any entity of aortic aneurysm, dissection, aortic stenosis and/or insufficiency. Patients with bacterial endocarditis were excluded from analysis. All surgical specimens were pathologically analysed according standard procedure. All specimens (n=19 in 2014, n=17 in 2015) with histological inflammation signs of aortitis being negative for tbc, mycosis, or lues were underwent further investigation searching for IgG4 +plasmacells, giant cells, and granuloma; all patients (n=36) were re-evaluated by a rheumatologist (immediately during the hospitalisation or within 3 weeks with outpatient presentation) including laboratory tests for RF, ANA, ANCA, ACCP, IgG subclasses, complement, ESR, CRP. Furthermore, all aortitis patients were investigated with MRI of aorta (n=15) or PET scan (n=17) or both (n=4) between 4 to 12 weeks after surgery to exclude persistent aortitis in native vessels. All patients which were diagnosed for aortitis through MRI and/or PET received immunosuppressive treatment containing glucocorticosteroids with or without synthetical or biological DMARDs.

Results: Patients after thoracic surgery of aortic valve and/or ascending aorta were positive tested for aortitis in 2014 with the frequency of 2.36% (n=19/806) and in 2015 2.54% (n=17/668). The mean age of the 36 cases were 61 (range 39–80), of them were male 55.5% (n=20). The pathologic findings described 14 cases typical for GCA, 6 with granuloma, one with IgG4 +plasmacells, and one with predominant lymphocytic infiltration, 14 with unspecific inflammation. Rheumatologic consultation in all 36 cases could evaluated in 6 patients a preexisting rheumatologic disorder (RA n=2, polymyalgia rheumatica (PMR) n=4) without treatment. One patient were positive for significant elevated serum levels of IgG4. MRI and/or PET scan documented aortitis spots in the native aorta with or without concerning iliac arteries and/or supra-aortic vessels. All imaging-positive aortitis patients (n=12) were treated with glucocorticosteroids according to the protocol for giant cell arteritis (prednisolone 1 mg/Kg/body weight), six patients additionally with methotrexate, one with tocilizumab and one with rituximab.

Conclusions: Only a small fraction of thoracic surgery patients with aortic aneurysm, dissection, aortic stenosis and/or insufficiency show histologic signs of aortitis. However, a third of them could be diagnosed via histological findings for active large vessel vasculitis after surgery.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7406

THU0446

USEFULNESS OF COLOUR DOPPLER ULTRASONOGRAPHY IN FOLLOW UP OF GIANT CELL ARTERITIS

H. Mukoyama, K. Nishimura, K. Kadoba, R. Saito, D. Waki, T. Yokota. *Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki-shi, Okayama, Japan*

Background: Colour doppler ultrasonography (CDU) in temporal arteries (TA) is useful for diagnosis and follow-up of giant cell arteritis (GCA).¹ However, the usefulness of CDU in carotid arteries (CA) for follow-up of GCA is not fully understood.²

Objectives: We investigated retrospectively relationship between clinical features and vessel wall thickness of TA and CA on CDU at baseline and during follow-up.

Methods: We recruited patients with newly diagnosed GCA in our hospital from January in 2004 to July in 2017. Among 35 patients, both of TA and CA were evaluated by CDU before and after treatment in 14 patients (four male and 10 female). Trained ultrasonographers and rheumatologists evaluated the CDU findings. Vessel wall thickness was evaluated at thickest portion of parietal or frontal ramus of TA, where biopsy was often performed. Intima-media thickness (IMT) of CA was also evaluated at thickest portion in each carotid artery.

Results: Average age was 73.2±11.3 years old. Follow-up periods after starting treatment were 244±149 weeks. All patients were diagnosed as GCA according to ACR criteria (1990) or temporal artery biopsy. Twelve patients were complicated with polymyalgia rheumatica (PMR) meeting EULAR/ACR classification criteria

(2012). All patients were treated with oral glucocorticoids (0.2 to 1.0 mg/kg prednisolone, 0.886 mg/kg on average). Immunosuppressants were added in four patients (methotrexate; n=3, tacrolimus; n=1). Aspirin was prescribed in nine patients.

Eleven patients (78.6%) had circumferential hypoechoic vessel wall thickness (halo sign) of TA at baseline, and halo signs disappeared in eight patients during follow-up. Average of vessel wall thickness significantly decreased from 0.665 mm to 0.311 mm (p=0.0016). The vessel wall thickness apparently increased in two patients out of three on clinical relapse, but it didn't increase in those who kept remission.

Graphical changes consistent with vasculitis in CA were observed in six patients, who showed hypoechoic thick intima and media on ultrasound or integration of FDG on PET/CT. Average of IMT in CA decreased from 1.167 mm to 0.883 mm (p=0.090) during follow-up in patients with vasculitis on CA. IMT changed little in patients without vasculitis on CA. Improvement rate was significantly higher in CA-involved patients than in CA-non-involved patients (p=0.043). IMT increased during follow-up in two CA-non-involved patients.

Abstract THU0446 – Table 1. Time-dependent change in vessel wall thickness of TA (mm)

	Baseline	Follow-up	Relapse
Patient 1	0.30	0.30	0.30
Patient 2	0.63	0.30	0.60
Patient 3	0.63	0.10	0.60

Abstract THU0446 – Table 2. Improvement rate of IMT in CA involved and non-involved patients

	IMT (mm)		Rate(B/A)	Median follow-up period (months)
	Baseline [A]	Follow-up [B]		
All (n=14)	0.964	0.843	0.874	30.0
CA involved (n=6)	1.167	0.883	0.757	34.0
CA non-involved (n=8)	0.813	0.813	1.000	27.6

Difference in B/A between CA involved and non-involved: p=0.043 (Mann-Whitney U test)

Conclusions: CDU of temporal arteries is useful for follow-up of GCA. CDU of carotid arteries has limited usefulness only in CA-involved patients.

REFERENCES:

- [1] Suelves AM, et al. Clin Ophthalmol. 2010; Nov 25;4:1383–4.
- [2] Hafner F, et al. Eur J Clin Invest 2014; 44(3):249–256.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.4657

THU0447

NO ADVANTAGE OF METHOTREXATE IN THE TREATMENT OF GIANT CELL ARTERITIS

I. Monjo Henry¹, on behalf of Luis Coronel², Ignacio Castaño³, Diana Peiteado¹, Sara García-Carazo¹, Alejandro Balsa¹, Eugenio de Miguel¹. ¹Rheumatology, Hospital Universitario La Paz, Madrid, Spain.; ²Rheumatology, Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de

Background: The high-dose glucocorticoids (GCs) are the mainstay of treatment in Giant Cell Arteritis (GCA). Patients treated with greater GCs dosages are at the greatest risk of morbidity. Immunosuppressive agents have been trialled in an effort to reduce toxicity from GCs and to improve efficacy of treatment. The results of one meta-analysis with the three trials that included methotrexate (MTX) showed a weak benefit in those patients receiving MTX, but the results were heterogeneous, with one trial showing significant benefit, while the other two did not.¹

Objectives: To study the efficacy and safety of MTX adjunct to GCs in the treatment of GCA.

Methods: New-onset giant-cell arteritis initiating treatment of the disease was included in a retrospective observational study to compare treatment efficacy and safety. According to the treatment received the patients were divided two groups: GCs alone (group 1) and MTX and GCs (group 2). To avoid bias, we defined a subgroup of patients in which only patients who started MTX in the first trimester of treatment were included (group 3). As efficacy outcome the number of relapses and the cumulative dose of GCs at 6, 12 and 24 months were collected. For safety,